News & Events
Tuesday, January 31, 2012
Soligenix Announces 1 for 20 Reverse-Split of its Common Stock
[read more]Thursday, January 26, 2012
Soligenix Receives $574,000 in Non-Dilutive Financing from New Jersey’s Technology Business Tax Certificate Transfer Program
[read more]Wednesday, January 18, 2012
Soligenix Demonstrates Robust Stability Results with its SGX204 Anthrax Vaccine
[read more]Thursday, December 15, 2011
Soligenix Initiates Next Generation Anthrax Vaccine Development Program under Agreement with Harvard University
[read more]Monday, December 12, 2011
Soligenix Announces Publication of Results of its Phase 2 Clinical Trial of orBec® in the Prevention of Acute GVHD
[read more]Monday, November 14, 2011
Soligenix Reports Third Quarter 2011 Financial Results
[read more]Tuesday, October 11, 2011
Soligenix Announces Formation of Pediatric Crohn’s Disease Medical Advisory Board
[read more]Thursday, September 15, 2011
Soligenix Announces Results of Recent Data Safety Monitoring Board Review for Phase 3 orBec® Study in Acute GI GVHD
[read more]Friday, August 12, 2011
Soligenix Reports Second Quarter 2011 Financial Results and Reviews Accomplishments
[read more]Thursday, July 28, 2011
Soligenix Announces Expansion of Partnership with Sigma-Tau Pharmaceuticals for orBec® in Europe
[read more]Monday, June 27, 2011
Soligenix Announces Appointment of Jerome Zeldis, MD, PhD and Keith Brownlie, CPA to its Board of Directors
[read more]Thursday, June 02, 2011
Soligenix Appoints Joseph Warusz as Vice President of Administration and Controller
[read more]Tuesday, March 29, 2011
Soligenix Reports Year-End 2010 Financial Results and
Highlights Recent Accomplishments
[read more]Wednesday, February 09, 2011
Soligenix to Present at 13th Annual BIO CEO & Investor Conference
[read more]Tuesday, February 01, 2011
Soligenix Appoints Kevin Horgan, MD, as Chief Medical Officer
[read more]Thursday, January 27, 2011
Soligenix Executes Exclusive License with the University of Colorado for Vaccine Thermostabilization Technology
[read more]Tuesday, January 25, 2011
Soligenix Receives $245,810 in Non-Dilutive Financing from New Jersey’s Technology Business Tax Certificate Transfer Program
[read more]Friday, January 21, 2011
Soligenix Receives FDA Orphan Drug Designation for RiVaxTM for the Prevention of Ricin Intoxication
[read more]Tuesday, January 18, 2011
Soligenix Announces Positive Preliminary Results of SGX202
in Radiation Injury
[read more]
